We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbCellera Biologics Inc | NASDAQ:ABCL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.2099 | 5.45% | 4.0599 | 3.71 | 4.90 | 4.20 | 3.92 | 3.92 | 2,202,875 | 05:00:00 |
From May 2019 to May 2024
By Michael Dabaie
AbCellera Biologics Inc. shares were up 8.5%, to $36.84, in Thursday morning trading.
AbCellera said before the market open that it would expand its collaboration with Gilead Sciences Inc., including a multi-year, multi-target antibody-discovery collaboration and access to AbCellera's humanized mouse technology, the Trianni Mouse.
AbCellera will receive an upfront payment and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.
Under the new agreement, AbCellera will generate panels of antibodies for up to eight new targets, across multiple indications, selected by Gilead.
Gilead shares were up 1.5%, to $65.60.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 01, 2021 10:22 ET (14:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AbCellera Biologics Chart |
1 Month AbCellera Biologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
